Adaptive Biotechnologies (ADPT) Q2 2026: Serial Testing Pull-Through Rises to 75%, Unlocking MRD Upside
Adaptive Biotechnologies’ Q2 results underscore robust momentum in MRD testing, with serial testing pull-through hitting 75% and clinical adoption expanding. Leadership’s disciplined capital approach and ongoing business separation efforts are setting up a sharper focus on MRD growth. Investors should watch for further serial testing gains and clarity on the IM business separation as key levers for future value creation.
Summary
- Serial Testing Expansion: Repeat order pull-through reached 75%, supporting higher MRD utilization.
- Separation Pathway Advances: Leadership prioritizes standalone MRD business and disciplined capital allocation.
- Upside Watch: Integration and clinical adoption initiatives could drive outperformance in the second half.
Business Overview
Adaptive Biotechnologies (ADPT) develops and commercializes next-generation sequencing-based diagnostics for immune-driven diseases. The company's core business is minimal residual disease (MRD) testing, which monitors cancer recurrence and treatment response, primarily in hematologic malignancies. Revenue is generated through clinical diagnostic testing and pharma partnerships, with a secondary focus on immune medicine (IM) as a potential future value lever.
Performance Analysis
Q2 delivered strong MRD testing growth, with leadership reaffirming full-year volume guidance of 38% to 40% growth off an expanded base. Serial testing pull-through, defined as the percentage of repeat orders fulfilled, increased to 75% from 72% in the prior quarter, reflecting successful adoption initiatives and improved integration with electronic medical record (EMR) systems such as Epic and OncoEMR. Pharma MRD revenues were robust but remain lumpy due to trial timing and sample flow, with leadership emphasizing ongoing strength in multiple myeloma and leukemia studies.
Clinical business execution remains a highlight, as the company leverages enhanced cell-free DNA (cfDNA) assays and workflow standardization to drive adoption. The IM business continues to be treated as a call option, with management emphasizing its separation as a key strategic priority. The balance sheet was bolstered by a recent convertible debt raise, offering flexibility for targeted growth investments.
- Serial Testing Gains: Pull-through improved to 75%, up from 60% in Q4, demonstrating progress in repeat testing and workflow integration.
- Pharma MRD Volatility: Revenue remains subject to clinical trial cadence, but underlying demand signals in myeloma and leukemia remain constructive.
- Separation and Capital: The IM business is being positioned for value maximization, supported by new capital from convertible debt.
Management’s prudent guidance reflects both strong first-half execution and a conservative stance on back-half pharma contributions, with upside potential tied to further serial testing adoption and clinical standardization.
Executive Commentary
"If you look at kind of the goalposts of an outcome, you know, I would say, I'm going to put this in kind of bunnier quotes, kind of the worst outcome, you know, in terms of that we have the MRD business is kind of Free and Clear and Separated to be able to kind of pursue its growth strategy. And like we've been talking about for the last couple of years is IM is really a call option."
Chad, CEO
"When we first measured Serial Testing back in Q4, the first full quarter we had to compare, we had 60% pull through. And now, as you noted, we've increased it to 75. And I think we would like to be able to apply the lessons we've learned in that setting with OncoEMR customers to other settings like our Epic customers."
Unidentified Executive, Company Executive
Strategic Positioning
1. Serial Testing Standardization
Serial testing, or repeat patient monitoring, is a major growth lever for MRD adoption. The company’s integration of custom interfaces with EMR platforms like Epic and OncoEMR has led to a steady increase in repeat order fulfillment. These workflow improvements are expected to drive consistent utilization and unlock incremental volume upside as more providers adopt standardized testing protocols.
2. MRD Platform Leverage and Expansion
MRD remains the core business, with leadership focused on maximizing its standalone growth trajectory post-separation. The enhanced cfDNA assay, launched last year, is positioned to further differentiate ADPT’s offering, while ongoing clinical evidence generation and market access initiatives are expected to cement leadership in hematologic cancers. Management continues to evaluate selective expansion into solid tumors and adjacent disease areas, but stresses disciplined criteria for any new investments.
3. IM Business Separation and Capital Allocation
The immune medicine (IM) segment is being actively separated, with Morgan Stanley advising on value-maximizing alternatives. The recent convertible debt raise strengthens the balance sheet, providing optionality for organic and inorganic growth. Leadership is clear that capital will be deployed only where ADPT can achieve high-margin, differentiated leadership, with a focus on long-term value creation for shareholders.
Key Considerations
This quarter’s results reflect both operational discipline and strategic repositioning. Investors should consider how serial testing adoption, business separation, and targeted capital deployment intersect to shape the company’s future earnings power and valuation.
Key Considerations:
- Serial Testing as a Growth Flywheel: Sustained gains in repeat testing could meaningfully lift MRD volume and revenue beyond current guidance.
- Clinical Workflow Integration: Success with Epic and OncoEMR integration may drive broader provider adoption and standardization across customer segments.
- Pharma Revenue Volatility: Lumpy pharma contributions remain a near-term swing factor, but underlying trial demand appears strong.
- Separation Execution and Capital Flexibility: The path and timing of IM separation, and subsequent capital allocation, will shape the next phase of MRD growth and competitive positioning.
Risks
Key risks include execution on serial testing standardization, potential delays or uncertainties in the IM business separation, and ongoing volatility in pharma MRD revenues tied to trial timing. Increased competition in the MRD market and reimbursement dynamics could also pressure future growth or margins. Management’s cautious guidance reflects these uncertainties, with upside tied to operational execution and market adoption.
Forward Outlook
For Q3, Adaptive Biotechnologies guided to:
- MRD volume growth in line with the 38% to 40% full-year target
- Continued serial testing adoption and expanded EMR integration
For full-year 2026, management maintained guidance:
- 38% to 40% MRD volume growth, matching last year’s percentage but off a larger base
Management highlighted several factors that could influence results:
- Potential upside from further serial testing standardization and workflow integration
- Ongoing volatility in pharma MRD revenue, balanced by strong clinical trends
Takeaways
Adaptive Biotechnologies is executing well on its MRD growth strategy, with serial testing and clinical workflow integration emerging as key drivers. The IM business separation remains a strategic wildcard, with capital allocation discipline central to the next phase. Investors should monitor progress on serial testing, business separation, and pharma trial dynamics as leading indicators of future performance.
- Serial Testing Traction: Workflow integration is driving higher repeat testing, creating a platform for sustained MRD revenue growth.
- Separation and Optionality: The IM business is being positioned as a call option, with separation expected to sharpen MRD focus and unlock value.
- Upside Catalysts: Watch for incremental serial testing gains, clinical adoption in new settings, and progress on business separation as key future levers.
Conclusion
ADPT’s Q2 results highlight disciplined execution and strategic clarity, with serial testing gains and business separation efforts positioning the company for continued MRD leadership. Future value creation will depend on operational follow-through and capital allocation as the business evolves.
Industry Read-Through
ADPT’s progress in serial testing integration and workflow standardization signals a broader trend toward clinical adoption in precision oncology diagnostics. The company’s focus on EMR integration and repeat testing could serve as a template for other diagnostic players aiming to drive utilization and stickiness. Separation of non-core assets and disciplined capital deployment are becoming best practices for diagnostics firms seeking to maximize core business value and optionality. Pharma trial revenue volatility remains an industry-wide challenge, underscoring the need for diversified growth drivers and operational agility.